Results 191 to 200 of about 57,323 (255)

Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019-2024. [PDF]

Front Oncol
Fuldeore R, Tan CJ, Kimura T, Farrokhi P, Yang R, Willis C, Asche C, Stenehjem D.   +7 more
europepmc   +1 more source

Single-cell RNA sequencing profiles drug activity within spatially engineered 3D cultures. [PDF]

Nat Commun
King JJ, Mowla A, Kretzmann JA, Bhalla N, Sugianto G, Norret M, Kadolsky UD, Iqbal M, Saxena A, Amos SE, Choi YS, Kennedy BF, Iyer KS, Smith NM, Evans CW.   +14 more
europepmc   +1 more source

A Comprehensive Review on Irinotecan-Induced Delayed Diarrhea: From Mechanisms to Therapeutic Options. [PDF]

Pharmaceuticals (Basel)
Wang Y, Li M, Hu Q, Liu J, Yang Q, Li Q, Zhu X, Dang H, Li H, Wang L, Peng B, Chen Y.   +11 more
europepmc   +1 more source

Irinotecan [PDF]

, 2020
openaire   +1 more source

High therapeutic efficacy of triplet therapy in unresectable or metastatic colorectal cancer and its optimal application strategies. [PDF]

Int J Clin Oncol
Sakuyama H, Okuyama H, Tahara Y, Tsukamoto S, Kita I, Nomura K, Murakami A, Okita Y, Satake H, Kato T, Tsuji A.   +10 more
europepmc   +1 more source

The phase I trial of preoperative short-course chemoradiotherapy with S-1/irinotecan and short-course radiation in locally advanced lower rectal cancer (SHOWTIME study). [PDF]

Radiat Oncol
Kojo K, Tanaka T, Yamanashi T, Miura H, Yokoi K, Kojima K, Yokota K, Kawakami S, Ishiyama H, Yamashita K, Kumamoto Y, Hiki N, Sato T, Naitoh T.   +13 more
europepmc   +1 more source

Patient-Derived Organoid and Single-Cell Multiomics Reveal Evolution Driven by CEACAM6/KRT19-Mediated Heterogeneity. [PDF]

FASEB J
Jing C, Wang Z, Cao H, Zhang Y, Huang Y, Yu Y, Li B, Ma R.   +7 more
europepmc   +1 more source

Extending the utility of anti-EGFR therapy in metastatic colorectal cancer. [PDF]

J Gastrointest Oncol
Cann C, Vijayvergia N.
europepmc   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source

Impact of <i>UGT1A1*28</i> polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. [PDF]

Future Oncol
Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A.   +10 more
europepmc   +1 more source